Connect with us

Headlines

Biotech Firm Receives $7.5M Grant for Glaucoma Research

The money comes from the German state of Saxony.

mm

Published

on

NEW YORK — Q BioMed Inc., a commercial stage biotech company, announced that its technology partner, Mannin, has received a $7.5M grant from the German state of Saxony.

The objective of the grant is to fund the development of novel pharmaceuticals and biologic treatments for glaucoma.

Podcast: Talking with the Finest, Hippest of Them All About Why There are No Ball Point Pens in Her Shop
INVISION Podcast

Podcast: Talking with the Finest, Hippest of Them All About Why There are No Ball Point Pens in Her Shop

Licensed or Not, Member or Not, the Opticians Association of America is Here for You [Podcast]
INVISION Podcast

Licensed or Not, Member or Not, the Opticians Association of America is Here for You [Podcast]

Drs. Adam Ramsey and Darryl Glover Talk About Fostering Relationships Between Black ECPs and the Industry at Large
INVISION Podcast

Drs. Adam Ramsey and Darryl Glover Talk About Fostering Relationships Between Black ECPs and the Industry at Large

The approval of the grant means that Q BioMed and Mannin “can significantly accelerate the development of these therapeutics,” according to a press release.

Denis Corin, CEO of Q BioMed, said, “We are thrilled that we will be able to speed the development of these promising therapeutics and bring new innovation to glaucoma patients as soon as possible. Our partnership with Mannin and now, the government of Saxony is important to the advancement of this unique drug platform and we look forward to supporting the build-out of the Mannin European headquarters in Leipzig.”

Mannin is a research-stage biotechnology company focused on the discovery, development and commercialization of therapeutics for vascular diseases. It was founded in July 2012 and is led by President and CEO Dr. George Nikopoulos. Q BioMed and Mannin have been partners since 2015.

Advertisement

George Nikopoulos, president and CEO of Mannin, stated, “We are very encouraged by the confidence and enthusiasm the government of Saxony has shown in our research, and we are committed to making accelerated progress through their investment.”

Mannin is leveraging two distinct modes of action to reduce the intraocular pressure that causes glaucoma, utilizing different routes of administration and dosing regimens. Mannin is currently working on the preclinical development of a small molecule pharmaceutical eye-drop as well as a novel recombinant protein injectable biologic. This approach “increases the probability of success of developing a new therapy that is optimized for the needs of glaucoma patients,” according to the release. Additionally, Mannin is exploring other therapeutic opportunities using these molecules for vascular diseases.

Q BioMed and Mannin intend to announce further details regarding the research program later this year.

Since launching in 2014, INVISION has won 23 international journalism awards for its publication and website. Contact INVISION's editors at [email protected].

Advertisement

SPONSORED VIDEO

SPONSORED BY SHAMIR

Shamir Glacier PLUS™UV

Utilizing the most advanced technologies, Shamir Glacier PLUS™ UV ensures you receive the most enhanced performance from your lenses.

Promoted Headlines

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular